THE HYDROXYCHLOROQUINE (HCQ) story got a major plot twist on May 25. Two months after US President Donald Trump waxed eloquent on the benefits of the antimalarial drug in treating Covid-19, the World Health Organization paused the HCQ arm of its multi-centre, multi-drug randomised clinical trial. (Patients who were getting the drug would complete their course, though.) The pause to review safety data from other trials signals that the hype over HCQ was misplaced, and that there is concern about its safety.
The decision, the WHO said, was taken in light of a large observational study published in The Lancet on May 22. The study showed that among one lakh patients from various countries who took the drug (alone or with an antibiotic), the death rate was higher and an increased frequency of irregular heartbeats was observed. Also, the researchers could not confirm any benefit from the drug in Covid-19 patients.
On the same day, the Indian government issued an advisory to expand the pool of personnel who would receive the drug as a preventive measure against the pandemic. The advisory said that cardiovascular side-effects were rare. The basis on which the Centre’s joint task force took this decision included three studies—a retrospective case-control study, an observational study at AIIMS and another investigation from three Central government hospitals—which, as per the advisory, indicated some benefits from taking HCQ for those with high exposure to Covid-19 patients.
Denne historien er fra June 07, 2020-utgaven av THE WEEK.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra June 07, 2020-utgaven av THE WEEK.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
William Dalrymple goes further back
Indian readers have long known William Dalrymple as the chronicler nonpareil of India in the early years of the British raj. His latest book, The Golden Road, is a striking departure, since it takes him to a period from about the third century BC to the 12th-13th centuries CE.
The bleat from the street
What with all the apps delivering straight to one’s doorstep, the supermarkets, the food halls and even the occasional (super-expensive) pop-up thela (cart) offering the woke from field-to-fork option, the good old veggie-market/mandi has fallen off my regular beat.
Courage and conviction
Justice A.M. Ahmadi's biography by his granddaughter brings out behind-the-scenes tension in the Supreme Court as it dealt with the Babri Masjid demolition case
EPIC ENTERPRISE
Gowri Ramnarayan's translation of Ponniyin Selvan brings a fresh perspective to her grandfather's magnum opus
Upgrade your jeans
If you don’t live in the top four-five northern states of India, winter means little else than a pair of jeans. I live in Mumbai, where only mad people wear jeans throughout the year. High temperatures and extreme levels of humidity ensure we go to work in mulmul salwars, cotton pants, or, if you are lucky like me, wear shorts every day.
Garden by the sea
When Kozhikode beach became a fertile ground for ideas with Manorama Hortus
RECRUITERS SPEAK
Industry requirements and selection criteria of management graduates
MORAL COMPASS
The need to infuse ethics into India's MBA landscape
B-SCHOOLS SHOULD UNDERSTAND THAT INDIAN ECONOMY IS GOING TO WITNESS A TREMENDOUS GROWTH
INTERVIEW - Prof DEBASHIS CHATTERJEE, director, Indian Institute of Management, Kozhikode
COURSE CORRECTION
India's best b-schools are navigating tumultuous times. Hurdles include lower salaries offered to their graduates and students misusing AI
